FDA to allow pharma companies modify COVID-19 shots amid variants surge

By Nikita Chaurasia  Date: 2021-02-24

FDA to allow pharma companies modify COVID-19 shots amid variants surge

With the rising cases of Coronavirus variants, the United States Food & Drug Administration (FDA) has reportedly introduced guidelines for pharmaceutical companies to modify their COVID-19 vaccine doses in an effort to curb the spread of the disease.

The FDA guidance introduced recently is specifically for companies making COVID-19 diagnostic, therapeutics, and vaccines, cited sources with relevant information.

As evidence suggests, Pfizer-BioNTech and Moderna’s COVID-19 doses, which have been approved for use in the United States, appear to offer protection against the new variants. However, with the virus continuing to mutate, pharma companies are required to adapt quickly to the evolving variants.

FDA’s newly issued groundwork will allow drug makers to react quickly to the emerging COVID-19 variants without the need for extended clinical trials to prove effectiveness and safety each time a new variant is discovered.

It is worth noting that the new development is similar to the flu shot changes that occur from year to year.

According to the Director of FDA’s Center for Biologics Evaluation and Research, Dr. Peter Marks, since flu shot is well studied, it is unnecessary to conduct clinical trials each year. He further claimed that drug manufacturers usually modify the shots based on the current strains that are likely to be in circulation.

Apart from having additional safety data, it is critical to understand whether the new vaccine can cover both the old as well as the new strain, Marks added. If the vaccine strain shows to be consistent, then the FDA could move towards the influenza-like model.

The new FDA guidelines also recommend producers of COVID-19 diagnostic tests as well as antibody treatment options to understand how emerging variants could impact their relevant effectiveness.

The U.S. Centers for Disease Control and Prevention may also relax some of its COVID-19 precautionary measures which were aimed at reducing the spread of the disease, sources claimed.

Source Credits –

https://www.nbcnews.com/health/health-news/fda-says-covid-vaccine-makers-can-modify-shots-variants-emerge-n1258528

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...